特发性肺纤维化的治疗方法。 - Suppr

Suppr

超能文献

Treatments for idiopathic pulmonary fibrosis.

作者信息

King Talmadge E, Noble Paul W, Bradford Williamson Z

出版信息

N Engl J Med. 2014 Aug 21;371(8):783-4. doi: 10.1056/NEJMc1407776.

DOI:10.1056/NEJMc1407776

PMID:25147884

Abstract

摘要

相似文献

Treatments for idiopathic pulmonary fibrosis.

N Engl J Med. 2014 Aug 21;371(8):783-4. doi: 10.1056/NEJMc1407776.

Treatments for idiopathic pulmonary fibrosis.

N Engl J Med. 2014 Aug 21;371(8):782. doi: 10.1056/NEJMc1407776.

Treatments for idiopathic pulmonary fibrosis.

N Engl J Med. 2014 Aug 21;371(8):782. doi: 10.1056/NEJMc1407776.

Treatments for idiopathic pulmonary fibrosis.

N Engl J Med. 2014 Aug 21;371(8):781. doi: 10.1056/NEJMc1407776.

Pirfenidone reduced disease progression in idiopathic pulmonary fibrosis.

Ann Intern Med. 2014 Oct 21;161(8):JC4-5. doi: 10.7326/0003-4819-161-8-201410210-02004.

A new hope for idiopathic pulmonary fibrosis.

N Engl J Med. 2014 May 29;370(22):2142-3. doi: 10.1056/NEJMe1403448. Epub 2014 May 18.

Pirfenidone for idiopathic pulmonary fibrosis, thrombocytosis in chronic obstructive pulmonary disease exacerbations, and a longitudinal study on e-cigarettes.

Am J Respir Crit Care Med. 2014 Sep 15;190(6):699-700. doi: 10.1164/rccm.201406-1188RR.

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE.

Novel treatments for idiopathic pulmonary fibrosis.

Am J Med. 2015 May;128(5):447-9. doi: 10.1016/j.amjmed.2015.01.003. Epub 2015 Jan 20.

Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):252-4. doi: 10.1164/rccm.201411-2044ED.

引用本文的文献

Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.

Nat Commun. 2022 Mar 23;13(1):1558. doi: 10.1038/s41467-022-29064-3.

Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.

Mol Ther. 2021 Apr 7;29(4):1487-1500. doi: 10.1016/j.ymthe.2021.01.028. Epub 2021 Jan 26.

Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis.

Front Pharmacol. 2020 Nov 27;11:593620. doi: 10.3389/fphar.2020.593620. eCollection 2020.

A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.

J Exp Med. 2019 Dec 2;216(12):2724-2735. doi: 10.1084/jem.20182351. Epub 2019 Oct 10.

Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells.

J Mol Med (Berl). 2019 Jul;97(7):973-990. doi: 10.1007/s00109-019-01787-9. Epub 2019 Apr 26.

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Respir Res. 2016 Feb 4;17:14. doi: 10.1186/s12931-016-0328-5.

Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis.

J Biol Chem. 2016 Mar 18;291(12):6433-46. doi: 10.1074/jbc.M115.693671. Epub 2016 Jan 27.

Living with Fibrosis: From Diagnosis to Future Hope.

Front Pharmacol. 2015 Dec 16;6:288. doi: 10.3389/fphar.2015.00288. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验